Data updated: May 26, 2026
Vonvendi (von willebrand factor (recombinant))
Approved 2015-12-07
1
Indication
--
Phase 3 Trials
10
Years on Market
Details
- Status
- Prescription
- First Approved
- 2015-12-07
- Patent Cliff
- 2029
- Routes
- Intravenous
- Dosage Forms
- For Injection
Companies
Website: ↗
Vonvendi Approval History
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2015 to 2015
Dec 2015 ORIGINAL
Update · CBER biologic (Purple Book)
What Vonvendi Treats
1 FDA approvalsOriginally approved for its first indication in 2015 .
- Other (1)
Other
(1 approval)- • Approved indication (Dec 2015)
📋
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07129343 | TAK-577-3002 | Ph 3 | recruiting | A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) |
| NCT02973087 results posted | 071301 2016-001478-14 | Ph 3 | completed | rVWF IN PROPHYLAXIS |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
Vonvendi FDA Label Details
Track Vonvendi with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.